1. Home
  2. HCAT vs ELDN Comparison

HCAT vs ELDN Comparison

Compare HCAT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HCAT
  • ELDN
  • Stock Information
  • Founded
  • HCAT 2008
  • ELDN 2004
  • Country
  • HCAT United States
  • ELDN United States
  • Employees
  • HCAT N/A
  • ELDN 31
  • Industry
  • HCAT Computer Software: Programming Data Processing
  • ELDN Biotechnology: Pharmaceutical Preparations
  • Sector
  • HCAT Technology
  • ELDN Health Care
  • Exchange
  • HCAT Nasdaq
  • ELDN Nasdaq
  • Market Cap
  • HCAT 259.8M
  • ELDN 176.1M
  • IPO Year
  • HCAT 2019
  • ELDN N/A
  • Fundamental
  • Price
  • HCAT $3.84
  • ELDN $2.99
  • Analyst Decision
  • HCAT Buy
  • ELDN Strong Buy
  • Analyst Count
  • HCAT 11
  • ELDN 1
  • Target Price
  • HCAT $8.36
  • ELDN $16.00
  • AVG Volume (30 Days)
  • HCAT 623.1K
  • ELDN 249.0K
  • Earning Date
  • HCAT 05-07-2025
  • ELDN 05-08-2025
  • Dividend Yield
  • HCAT N/A
  • ELDN N/A
  • EPS Growth
  • HCAT N/A
  • ELDN N/A
  • EPS
  • HCAT N/A
  • ELDN N/A
  • Revenue
  • HCAT $306,584,000.00
  • ELDN N/A
  • Revenue This Year
  • HCAT $11.30
  • ELDN N/A
  • Revenue Next Year
  • HCAT $9.79
  • ELDN N/A
  • P/E Ratio
  • HCAT N/A
  • ELDN N/A
  • Revenue Growth
  • HCAT 3.60
  • ELDN N/A
  • 52 Week Low
  • HCAT $3.60
  • ELDN $1.55
  • 52 Week High
  • HCAT $9.24
  • ELDN $5.54
  • Technical
  • Relative Strength Index (RSI)
  • HCAT 38.82
  • ELDN 39.03
  • Support Level
  • HCAT $3.56
  • ELDN $2.63
  • Resistance Level
  • HCAT $4.31
  • ELDN $3.21
  • Average True Range (ATR)
  • HCAT 0.33
  • ELDN 0.24
  • MACD
  • HCAT -0.01
  • ELDN 0.03
  • Stochastic Oscillator
  • HCAT 26.05
  • ELDN 45.24

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: